TEVOGEN BIO

Thank you Linda Lindner and ROI-NJ “By overcoming significant capital and time barriers of entry needed to build GMP capabilities at scale, this venture is expected to significantly expedite both research and manufacturing,” Ryan Saadi, MD, MPH, CEO of TEVOGEN BIO, said. “This facility will be instrumental in advancing our mission to bring innovative solutions to market with speed and cost efficiency.” https://lnkd.in/g97M2h73

We welcome you to meet Tevogen's leadership team at the 43rd Annual J.P. Morgan Healthcare Conference. #TVGN TEVOGEN BIO J.P. Morgan #Healthcare #affordable #accessible #celltherapy #biotech

Link: https://lnkd.in/gWkEhVKd ▪ CD8 Technology Services, LLC (“CD8 Technology”) to provide turn-key facility for Tevogen Bio ▪ Reinforces Tevogen Bio’s commitment to preserving shareholder value ▪ Expected to further enhance Tevogen Bio’s ambitious growth agenda #TVGN #affordable #accessible #celltherapy #biotech

#TVGN #affordable #accessible #celltherapy #biotech

Link: https://lnkd.in/gsWDAgrA Tevogen Bio provides additional guidance on the first clinical product of the company’s proprietary ExacTcell technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients, and a subgroup of patients with post-acute sequelae of SARS-CoV-2 (PASC). Tevogen Bio’s recently shared forecast reflects its business plan of market entry by the end of 2026. #TVGN #affordable #accessible #celltherapy #biotech

Link: https://lnkd.in/gsXDwwDb Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development The partnership with Microsoft, the leading innovator in the AI space, is a substantial investment in Tevogen’s goal to provide affordable and accessible therapies. By leveraging Microsoft’s cutting-edge AI technology, Tevogen aims to push the boundaries of what AI can achieve in the biotech industry. #TVGN Microsoft #artificalintelligence #biotech #AI

Link: https://lnkd.in/gtaYuBhP Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion · Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2. · Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years. #TVGN #affordable #accessible #celltherapy #biotech #LongCOVID

Link: https://lnkd.in/g9sShmEx • Total eligible patients in the US exceed 2 million. • Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment. • Reflects business philosophy of commercial success through patient accessibility. "At Tevogen, we strive to turn our vision into reality ensuring our commitment translates into tangible results. Our priority is the well-being of cancer patients. With compelling evidence that SARS-CoV-2 remains a serious threat to those undergoing immunosuppressive treatments and chemotherapy, our first pivotal study with TVGN 489 is being designed specifically to help these vulnerable patients combat the infection," commented Sadiq Khan, Chief Commercial Officer. #TVGN #affordable #accessible #celltherapy #biotech Nasdaq TEVOGEN BIO

Link: https://lnkd.in/gvFjMgDZ “We are impressed by Leadership's extensive industry experience resulting in achieving key milestones in record times including granted patents and a product pipeline in multiple therapeutic areas. In 2022, Tevogen Bio was named as the highest-valued biotech unicorn at $4.2 billion. With further advancements, including positive proof-of-concept clinical trial, we estimate current market value of its robust intellectual property and product portfolio excluding other assets to exceed $10 billion in current market value with significant revenue potential,” said Hema Patel, Managing Partner of HMP Partners and The Patel Family LLP. #TVGN #affordable #accessible #celltherapy #biotech

Link: https://lnkd.in/gB8ZySgx • Approximately one in three women remain HPV positive after cervical procedures for precancerous lesions. • Tens of thousands of women in the US each year are diagnosed with high-grade cervical precancerous lesions. • These high-grade cervical lesions can reoccur, requiring more treatment, and potentially lead to cervical cancer. • Nearly all cervical cancer and high-grade cervical lesions are associated with HPV which promotes cancer formation. • The primary risk factor for the recurrence of high-grade cervical lesions is the continued presence of HPV after procedure. • HPV is the most common sexually transmitted disease in the world and represents a significant public health burden as persistent infections can lead to cancer in the cervix as well as other areas of the body such as the mouth and throat. #TVGN #affordable #accessible #celltherapy #biotech #CervicalCancer #HPV #oncology